References for "Inherited Predisposition to Cancer" by Heather L. Shappell, MS, Thomas S. Frank, MD, and Greg Critchfield, MD. Dallas Medical Journal. 2002;88:389-392.

1. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
2. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet. 1999;36:801-818.
3. Jarvinen HJ. Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival. Gut 1992;33:357-360.
4. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.
5. Claus EB, Schildkraut J, Iversen ES Jr, Berry D, Parmigiani G. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history. J Natl Cancer Inst. 1998;90:1824-1829.
6. Lynch H, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch Syndrome): an updated review. Cancer. 1996;78:1149-1167.
7. Park JG, Vasen HF, Park KJ, et al. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum. 1999;42:710-715.
8. Petersen GM. Genetic testing and counseling in familial adenomatous polyposis. Oncology (Huntingt). 1996;10:89-94.
9. American Cancer Society. Cancer Facts and Figures, 2001.
10. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692-695.
11. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
12. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
13. Easton DF, Ford D, Bishop DT, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56:265-271.
14. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996;14:1730-1736.
15. Eng C, Brody LC, Wagner TM, et al. Interpreting epidemiological research: blinded comparison of methods used to estimate the prevalence of inherited mutations in BRCA1. J Med Genet. 2001;38:824-833.
16. NIH consensus conference. Ovarian cancer. Screening, treatment and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995;273:491-497.
17. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
18. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
20. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356:1876-1881.
21. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001;286:2251-2256.
22. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235-240.
23. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med. 1998;339:424-428.
24. Lynch PM. Clinical challenges in management of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer. Cancer. 1999;86:2533-2539.
25. Ponder B. Genetic testing for cancer risk. Science. 1997;278:1050-1054.
26. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet. 1997;60:496-504.
27. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999;91:1310-1316.
28. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218.
29. Lynch HT, Harris RE, Lynch PM, Guirgis HA, Lynch JF, Bardawil WA. Role of heredity in multiple primary cancer. Cancer. 1977;40:1849-1854.
30. Nugent KP, Spigelman AD, Phillips RK. Risk of extracolonic cancer in familial adenomatous polyposis. Br J Surg. 1996;83:1121-1122.
31. Burt RW. Colon cancer screening. Gastroenterology. 2000;119:837-853.
32. Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut. 1998;43:548-552.
33. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum. 1993;36:1059-1062.
34. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277:997-1003.
35. Burke W, Petersen G, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA. 1997;277:915-919.
36. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633-1637.
37. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121:198-213.
38. Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer. 1995;76:2427-2433.
39. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-1952.

References for "Locally Advanced Non-Small-Cell Lung Cancer" by Claude A. Denham, MD. Dallas Medical Journal. 2002;88:393-396.

1. Greenlee RT, Hill-Harman MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Schrek R, Baker LA, Ballard GP, et al. Tobacco smoking as an etiologic factor in disease: cancer. Cancer Res. 1950;10:49-58.
3. Garfinkel L, Silverberg E. Lung cancer and smoking trends in the United States over the past 25 years. CA Cancer J Clin. 1991;41:137-145.
4. Kabat GC. Aspects of the epidemiology of lung cancer in smokers and nonsmokers in the United States. Lung Cancer. 1996;15:1-20.
5. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
6. Glazer HS, Kaiser LR, Anderson DJ, et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology. 1989;173:37-42.
7. Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancer: approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990;141:1096-1101.
8. Izbicki JR, Thetter O, Karg O, et al. Accuracy of computed tomographic scan and surgical assessment for staging of bronchial carcinoma: a prospective study. J Thorac Cardiovasc Surg. 1992;104:413-420.
9. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med. 2000;343:254-261.
10. Van Tinteren H, Hoekstra O, Smit E, et al. Randomized controlled trial to evaluate the cost effectiveness of positron emission tomography added to conventional diagnosis in non-small-cell lung cancer. Proc Am Soc Clin Oncol. 2000;19:482a.
11. Detterbeck FC, Jones DR, Parker LA. Intrathoracic staging. In: Detterbeck FC, et al, eds. Diagnosis and Treatment of Lung Cancer. An Evidence-Based Guide for the Practicing Clinician. Philadelphia, Pa: WB Saunders; 2001:73-93.
12. Pearson FG, DeLarue NC, Iives R, Todd TR, Cooper JD. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with respectable cancer of the lung. J Thorac Cardiovasc Surg. 1982;83:1-11.
13. Hatter J, Kohman LJ, Mosca RS, Graziano SL, Veit LJ, Coleman M. Preoperative evaluation of stage I and stage II non-small-cell lung cancer. Ann Thorac Surg. 1994;58:1738-1741.
14. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am J Respir Crit Care Med. 1995;152:225-230.
15. Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small-cell lung cancer. Chest. 1991;100:422-428.
16. Hara N, Ohta M, Tanaka K, et al. Assessment of the role of surgery for stage III bronchogenic carcinoma. J Surg Oncol. 1984;25:153-158.
17. Detterbeck FC, Jones DR. Surgical treatment on stage IIIA (N2) non-small-cell lung carcinoma. In: Detterbeck FC, et al, eds. Diagnosis and Treatment of Lung Cancer. An Evidence Based Guide for the Practicing Clinician. Philadelphia, Pa: WB Saunders; 2001:244-256.
18. Effects of postoperative mediastinal radiation on completely resected stage II and III epidermoid cancer of the lung. The Lung Cancer Sudy Group. N Engl J Med. 1986;315:1377-1381.
19. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998;352:257-263.
20. Shaw RR, Paulson DL, Kee JL. Treatment of superior sulcus tumors by irradiation followed by resection. Ann Surg. 1961;154:29-40.
21. Kraut MJ, Rusch VW, Crowley JJ, et al. Induction chemotherapy plus surgical resection is a feasible and highly effective treatment for Pancoast tumors: initial results of SWOG 9416 (Intergroup 0610) trial. Proc Am Soc Clin Oncol. 2000;19:487a.
22. Scott C, Sause WT, Byhardt R, et al. Recursive partitioning analysis of 1592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small-cell lung cancer. Lung Cancer. 1997;17:S59-S74.
23. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
24. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Canc Inst. 1995;87:190-205.
25. Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol. 1986;4:710-715.
26. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med. 2000;343:1217-1222.
27. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-158.
28. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
29. DePierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small-cell lung carcinoma. J Clin Oncol. 2002;20:247-253.
30. Fleck J, Camargo J, Goday D, et al. Chemoradiation therapy vs chemotherapy alone as a neoadjuvant treatment for stage III non-small-cell lung cancer: preliminary report of a phase III prospective randomized trial. Proc Am Soc Clin Oncol. 1993;12:333a.
31. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14:1065-1070.
32. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatinum in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699.
33. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol. 2000;19:484a.
34. Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small-Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
35. Sederholm, C. Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: a phase III study by the Swedish Lung Cancer Study Group. Proc Am Soc Clin Oncol. 2002;21:291a.
36. Lilenbaum RC, Herndon J, List M, et al. Single agent vs combination chemotherapy in advanced non-small-cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost effectiveness. Proc Am Soc Clin Oncol. 2002;21:2a.
37. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small lung carcinoma. N Engl J Med. 2002;346:92-98.
38. Gaspar L, Gandara D, Chansky D, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIB non-small-cell lung carcinoma (NSCLC) (SWOG 9504): patterns of failure and updated survival. Proc Am Soc Clin Oncol. 2001;20:315a.
39. Choy H, Curran WJ, Scott CB, et al. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427-a randomized phase II study of 3 chemoradiation regimens with paclitaxel/carboplatin and thoracic radiation for patients with locally advanced non-small-cell carcinoma. Proc Am Soc Clin Oncol. 2002;21:291a.
40. Kubota K, Furuse K, Kawahara M, et al. Role of radiotherapy in combine modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol. 1994;12:1547-1552.
41. DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase III trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel to CP alone in patients with stage IIIB/IV non-small-cell lung cancer. Proc Am Soc Clin Oncol. 2000;19:485a.
42. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (“Iressa”) in advanced non-small-cell lung carcinoma patients who had failed platinum and docetaxel based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 2002;21:292a.